EGFR and cancer: A plethora of recent studies has unveiled various determinants contributing to lenvatinib resistance including activation of the epidermal growth factor receptor (EGFR), overexpression of fibroblast growth factor receptor 1 (FGFR1), the emergence of cancer stem cells, a hypoxic microenvironment, an immunosuppressive microenvironment, extracellular matrix remodeling, and metabolic reprogramming [22].